FGH Biotech
Houston, US · Founded 2011 · Delaware corporation
Find your way into FGH Biotech
FGH BioTech develops small molecule drugs that regulate SREBP transcription factors and related pathways, targeting the prevention and treatment of metabolic diseases and cancer. The company's work is based on decades of research in fat and energy metabolism.
Founders & leadership
FGH Biotech was founded in 2011 by Salih J. Wakil PhD, Motonari Uesugi PhD, and Lutfi Abu-Elheiga PhD.
SJ
Salih J. Wakil PhDFounder
MU
Motonari Uesugi PhDFounder
LA
Lutfi Abu-Elheiga PhDFounder
LA
Lufti Abu-ElheigaExecutive
JW
Joe WakilExecutive
Board
AK
Adam KuspaBoard director
Reported raises · per SEC filings
Form D private placements$2.1M disclosed across 1 of 2 rounds · 2015–2017
▶$2.1MraisedMay 2018 · 18 investors · PharmaceuticalsRule 506(b)
▶$2.1MraisedMay 2018 · 18 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Lufti Abu-ElheigaExecutive Officer
- Joe WakilExecutive Officer, Director
- Salih J WakilExecutive Officer, Director
- Adam KuspaDirector
- Offering amount
- $4M
- Amount sold
- $2.1M
- Minimum investment
- $12.5K
- First sale
- Oct 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.5MofferedNov 2015 · PharmaceuticalsRule 506(b)
▶$2.5MofferedNov 2015 · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Adam KuspaDirector
- Lufti Abu-ElheigaExecutive Officer
- Joe WakilExecutive Officer, Director
- Salih J WakilExecutive Officer, Director
- Offering amount
- $2.5M
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2014 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $324.5K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does FGH Biotech do?
- FGH BioTech develops small molecule drugs that regulate SREBP transcription factors and related pathways, targeting the prevention and treatment of metabolic diseases and cancer. The company's work is based on decades of research in fat and energy metabolism.
- Who founded FGH Biotech?
- FGH Biotech was founded by Salih J. Wakil PhD, Motonari Uesugi PhD, Lutfi Abu-Elheiga PhD in 2011.
- How much funding has FGH Biotech raised?
- FGH Biotech has disclosed $2.1M raised across 1 of its 2 known rounds.
- Where is FGH Biotech headquartered?
- FGH Biotech is headquartered in Houston, US.